Abstract
The discovery of autoantibodies against M-type phospholipase A2 receptor (PLA2R1)1 as the main cause of membranous nephropathy (MN) has revolutionized diagnosis, prognostication, and treatment approaches in patients with MN.2 Different assays have been established for the detection of circulating PLA2R1 antibodies.2 Although Western blot is more sensitive, enzyme-linked immunosorbent assay (ELISA) and the indirect immunofluorescence test (IIFT) are commercially widely available and routinely used for the diagnosis and to make treatment decisions in patients with MN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
